DGX - Quest Diagnostics Inc Stock Price, Fair Value and News

137.02USD+0.08 (+0.06%)Delayed as of 08 May 2024, 03:23 pm ET

Market Summary

USD137.02+0.08

Delayedas of 08 May 2024, 03:23 pm

0.06%

DGX Alerts

1 major insider sales recently.

DGX Stock Price

View Fullscreen

DGX RSI Chart

DGX Valuation

Market Cap

15.2B

Price/Earnings (Trailing)

17.98

Price/Sales (Trailing)

1.64

EV/EBITDA

13.18

Price/Free Cashflow

16.07

DGX Price/Sales (Trailing)

DGX Profitability

Operating Margin

32.87%

EBT Margin

12.05%

Return on Equity

13.08%

Return on Assets

6.06%

Free Cashflow Yield

6.22%

DGX Fundamentals

DGX Revenue

Revenue (TTM)

9.3B

Rev. Growth (Yr)

1.5%

Rev. Growth (Qtr)

3.41%

DGX Earnings

Earnings (TTM)

846.0M

Earnings Growth (Yr)

-3.96%

Earnings Growth (Qtr)

1.04%

Breaking Down DGX Revenue

52 Week Range

119.59145.58

(Low)(High)

Last 7 days

-0.9%

Last 30 days

4.8%

Last 90 days

7.5%

Trailing 12 Months

1.7%

How does DGX drawdown profile look like?

DGX Financial Health

Current Ratio

0.97

Debt/Equity

0.59

Debt/Cashflow

0.35

DGX Investor Care

Dividend Yield

2.1%

Dividend/Share (TTM)

2.88

Buy Backs (1Y)

0.81%

Diluted EPS (TTM)

7.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.3B	0	0	0
2023	9.6B	9.5B	9.3B	9.3B
2022	10.7B	10.6B	10.3B	9.9B
2021	10.3B	11.1B	11.0B	10.8B
2020	7.7B	7.5B	8.4B	9.4B
2019	7.5B	7.6B	7.6B	7.7B
2018	7.5B	7.5B	7.6B	7.5B
2017	7.5B	7.4B	7.4B	7.4B
2016	7.5B	7.5B	7.5B	7.5B
2015	7.5B	7.6B	7.5B	7.5B
2014	7.2B	7.3B	7.4B	7.4B
2013	7.3B	7.2B	7.2B	7.1B
2012	7.5B	7.5B	7.5B	7.4B
2011	7.4B	7.4B	7.4B	7.4B
2010	7.5B	7.4B	7.4B	7.4B
2009	7.3B	7.3B	7.4B	7.5B
2008	0	6.9B	7.1B	7.2B
2007	0	0	0	6.7B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Quest Diagnostics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 29, 2024	kuppusamy karthik	sold	-246,400	140	-1,760	svp, clinical solutions
Apr 22, 2024	samad sam	acquired	3,029	126	24.00	executive vice president & cfo
Apr 22, 2024	gregg vicky b	acquired	10,225	126	81.00	-
Apr 22, 2024	plewman patrick	acquired	8,710	126	69.00	svp for diagnostic services
Apr 22, 2024	kuppusamy karthik	acquired	5,681	126	45.00	svp, clinical solutions
Mar 26, 2024	plewman patrick	sold (taxes)	-14,604	128	-114	svp for diagnostic services
Mar 26, 2024	delaney mark e	sold (taxes)	-21,778	128	-170	svp & chief commercial officer
Feb 29, 2024	doherty catherine t.	sold	-149,420	125	-1,187	evp, regional businesses
Feb 29, 2024	prevoznik michael e	sold	-706,313	125	-5,611	svp & general counsel
Feb 28, 2024	deppe michael j	sold (taxes)	-13,773	126	-109	svp, corp. controller & cao

Which funds bought or sold DGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Empowered Funds, LLC	added	892	2,524,770	2,818,870	0.05%
May 06, 2024	Jefferies Financial Group Inc.	reduced	-26.09	-183,528	937,584	0.01%
May 06, 2024	OLD SECOND NATIONAL BANK OF AURORA	unchanged	-	-2,223	62,029	0.02%
May 06, 2024	AM Squared Ltd	new	-	53,244	53,244	0.13%
May 06, 2024	Envestnet Portfolio Solutions, Inc.	added	35.29	1,447,720	6,176,800	0.02%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-683,532	-	-%
May 06, 2024	Integrated Advisors Network LLC	unchanged	-	-10,224	287,142	0.01%
May 06, 2024	Investors Research Corp	unchanged	-	-4,813	134,308	0.03%
May 06, 2024	Empirical Finance, LLC	added	3.25	-1,792	561,724	0.03%
May 06, 2024	Addison Advisors LLC	unchanged	-	-5,604	156,405	0.05%

Are Funds Buying or Selling DGX?

Are funds buying DGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DGX

No. of Funds

DGX Alerts

1 major insider sales recently.

Unveiling Quest Diagnostics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.07%	13,575,974	SC 13G/A
Jan 25, 2024	state street corp	4.76%	5,352,341	SC 13G/A
Jan 24, 2024	blackrock inc.	9.4%	10,578,025	SC 13G/A
Feb 09, 2023	vanguard group inc	12.27%	13,973,339	SC 13G/A
Feb 07, 2023	state street corp	5.16%	5,879,980	SC 13G/A
Jan 23, 2023	blackrock inc.	10.9%	12,391,327	SC 13G/A
Apr 08, 2022	blackrock inc.	10.7%	12,807,624	SC 13G/A
Feb 10, 2022	state street corp	5.11%	6,268,789	SC 13G
Feb 07, 2022	blackrock inc.	9.5%	11,636,382	SC 13G/A
Feb 10, 2021	vanguard group inc	10.64%	14,337,685	SC 13G/A

Recent SEC filings of Quest Diagnostics Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	4	Insider Trading
Apr 29, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 25, 2024	144	Notice of Insider Sale Intent
Apr 24, 2024	10-Q	Quarterly Report
Apr 23, 2024	8-K	Current Report
Apr 11, 2024	PX14A6G	PX14A6G

Peers (Alternatives to Quest Diagnostics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	184.3B	23.7B	1.86%	4.00%	41.87	7.76	-8.94%	-35.91%
A	41.4B	6.7B	-1.98%	6.66%	33.5	6.15	-2.81%	-6.58%
IDXX	40.0B	3.7B	-6.80%	-0.27%	46.15	10.74	8.57%	23.94%
DGX	15.2B	9.3B	4.84%	1.65%	17.98	1.64	-3.29%	6.68%
MEDP	12.5B	2.0B	0.34%	91.91%	39.87	6.35	25.57%	21.62%
CRL	12.1B	4.1B	-6.65%	24.43%	25.56	2.94	3.86%	-2.39%
NTRA	11.7B	1.1B	0.49%	83.09%	-27	10.84	31.99%	20.63%
EXAS	11.1B	2.5B	-12.56%	-10.42%	-54.61	4.46	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-13.59%	-27.74%	1.7K	2.89	28.93%	111.61%
GH	2.3B	563.9M	6.75%	-20.02%	-4.78	4.06	25.45%	26.76%
SMALL-CAP
CDNA	542.6M	280.3M	8.83%	27.65%	-2.85	1.94	-12.89%	-148.37%
ACRS	95.5M	31.1M	14.29%	-83.81%	-1.24	3.07	0.95%	19.75%
APDN	61.1M	9.0M	833.33%	253.40%	-8.46	6.79	-53.31%	2.21%
AWH	36.4M	9.2M	11.36%	-35.81%	-2.18	3.98	11.85%	44.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Quest Diagnostics Inc News

Latest updates

Quest Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.4%	2,366	2,288	2,295	2,338	2,331	2,333	2,486	2,453	2,611	2,744	2,774	2,550	2,720	3,002	2,786	1,827	1,822	1,926	1,956	1,953	1,891
Cost Of Revenue	2.8%	1,595	1,552	1,541	1,546	1,560	1,575	1,618	1,611	1,646	1,718	1,670	1,565	1,626	1,733	1,580	1,221	1,270	1,264	1,264	1,265	1,244
Costs and Expenses	2.2%	2,066	2,021	1,953	1,990	2,026	2,198	2,094	2,065	2,098	2,208	2,122	2,017	2,060	2,207	2,068	1,544	1,647	1,563	1,643	1,646	1,643
S&GA Expenses	8.1%	440	407	380	416	439	563	464	422	425	464	427	429	407	447	396	360	347	349	362	362	384
EBITDA Margin	-1.1%	0.15*	0.15*	0.14*	0.14*	0.14*	0.16*	0.19*	0.21*	0.25*	0.26*	0.28*	0.29*	0.25*	0.22*	0.20*	0.15*	0.15*	0.16*	-	-	-
Interest Expenses	-7.5%	-43.00	-40.00	-40.00	-37.00	-35.00	-32.00	-33.00	-36.00	-37.00	-37.00	-38.00	-38.00	-38.00	-39.00	-42.00	-41.00	-41.00	-42.00	-44.00	-45.00	-44.00
Income Taxes	65.0%	66.00	40.00	68.00	75.00	65.00	-4.00	81.00	77.00	110	114	153	177	153	191	177	66.00	26.00	72.00	62.00	63.00	50.00
Earnings Before Taxes	12.2%	266	237	299	317	277	109	351	323	452	502	654	817	626	758	753	255	118	328	270	265	213
EBT Margin	-1.3%	0.12*	0.12*	0.11*	0.11*	0.11*	0.12*	0.16*	0.18*	0.23*	0.24*	0.26*	0.27*	0.23*	0.20*	0.17*	0.13*	0.13*	0.14*	-	-	-
Net Income	1.0%	194	192	225	235	202	101	256	234	355	390	505	631	469	579	568	185	99.00	253	215	226	164
Net Income Margin	-1.3%	0.09*	0.09*	0.08*	0.08*	0.08*	0.10*	0.12*	0.14*	0.18*	0.18*	0.20*	0.20*	0.17*	0.15*	0.13*	0.10*	0.10*	0.11*	-	-	-
Free Cashflow	-89.0%	50.00	455	102	340	-33.00	187	384	326	417	337	472	376	645	379	771	273	164	176	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.5%	13,954	14,022	13,482	13,425	12,794	12,837	13,223	13,312	13,442	13,611	13,572	12,861	13,931	14,026	14,143	12,990	12,049	12,843	12,019	11,760	11,937
Current Assets	-6.1%	2,228	2,372	1,815	1,733	1,814	1,898	2,334	2,426	2,475	2,741	2,854	2,146	2,999	3,058	3,348	2,380	1,560	2,490	1,779	1,566	1,778
Cash Equivalents	-30.9%	474	686	143	126	175	315	700	790	712	872	987	560	1,230	1,158	1,605	988	342	1,192	434	273	464
Inventory	-4.7%	181	190	184	184	190	192	183	187	197	208	205	199	223	223	205	154	126	123	112	105	98.00
Net PPE	-0.3%	1,810	1,816	1,830	1,814	1,795	1,766	1,707	1,664	1,668	1,707	1,634	1,622	1,624	1,627	1,544	1,505	1,461	1,453	1,351	1,307	1,277
Goodwill	1.3%	7,830	7,733	7,732	267	7,241	7,220	7,190	7,195	7,197	7,095	7,057	7,045	6,870	6,873	6,880	6,789	93.00	-	-	-	-
Current Liabilities	26.6%	2,298	1,815	1,618	1,875	1,355	1,551	1,602	1,577	1,700	1,753	1,759	1,551	1,707	1,776	2,389	1,843	1,129	1,990	2,011	1,904	2,282
Long Term Debt	-13.7%	3,804	4,410	3,946	3,777	3,975	3,978	3,980	3,983	3,985	4,010	4,006	4,008	4,010	4,013	4,018	4,020	4,033	3,966	3,188	3,169	3,131
LT Debt, Current	199.0%	906	303	304	518	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	555	555	3.00	804	-	-	-
Shareholder's Equity	2.0%	6,432	6,307	6,425	6,287	6,088	5,930	6,272	6,450	6,415	6,483	6,432	5,940	6,790	6,809	6,446	5,881	5,703	5,687	5,654	5,509	5,341
Retained Earnings	1.2%	8,935	8,825	8,711	8,566	8,412	8,290	8,263	8,083	7,926	7,649	7,333	10,246	9,690	9,303	8,800	8,307	8,197	8,174	7,992	7,849	7,694
Additional Paid-In Capital	-1.2%	2,292	2,320	2,302	2,284	2,266	2,295	2,272	2,250	2,226	2,260	1,936	2,555	2,824	2,841	2,801	2,764	2,738	2,722	2,705	2,686	2,671
Shares Outstanding	-	111	-	112	112	112	-	116	117	119	-	127	125	133	-	134	134	134	-	135	135	134
Minority Interest	5.7%	37.00	35.00	38.00	38.00	38.00	37.00	37.00	39.00	38.00	39.00	40.00	41.00	45.00	50.00	46.00	50.00	46.00	46.00	49.00	50.00	51.00
Float	-	-	-	-	15,700	-	-	-	15,400	-	-	-	16,100	-	-	-	15,200	-	-	-	13,700	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-70.8%	154	527	207	444	94.00	334	502	402	480	481	561	460	731	541	862	355	247	348	299	321	275
Share Based Compensation	15.8%	22.00	19.00	18.00	16.00	24.00	22.00	18.00	19.00	18.00	19.00	21.00	21.00	18.00	34.00	32.00	17.00	14.00	12.00	12.00	15.00	17.00
Cashflow From Investing	-86.8%	-213	-114	-107	-682	-158	-174	-118	-82.00	-169	-227	-96.00	437	-93.00	-168	-193	-205	-206	-100	-109	-92.00	-110
Cashflow From Financing	-217.7%	-153	130	-83.00	189	-76.00	-545	-474	-242	-471	-369	-38.00	-1,567	-566	-820	-52.00	496	-891	510	-29.00	-420	164
Dividend Payments	-1.2%	79.00	80.00	80.00	80.00	74.00	75.00	78.00	78.00	74.00	77.00	76.00	81.00	75.00	75.00	76.00	75.00	71.00	71.00	72.00	71.00	72.00
Buy Backs	-100.0%	-	275	-	-	-	461	374	200	373	289	-	1,500	410	250	-	-	75.00	200	50.00	50.00	53.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DGX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 2,366	$ 2,331
Operating costs and expenses and other operating income:
Cost of services	1,595	1,560
Selling, general and administrative	440	439
Amortization of intangible assets	29	26
Other operating expense, net	2	1
Total operating costs and expenses, net	2,066	2,026
Operating income	300	305
Other income (expense):
Interest expense, net	(43)	(35)
Other income, net	9	7
Total non-operating expense, net	(34)	(28)
Income before income taxes and equity in earnings of equity method investees	266	277
Income tax expense	(66)	(65)
Equity in earnings of equity method investees, net of taxes	8	5
Net income	208	217
Less: Net income attributable to noncontrolling interests	14	15
Net income attributable to Quest Diagnostics	$ 194	$ 202
Earnings per share attributable to Quest Diagnostics’ common stockholders:
Basic (in dollars per share)	$ 1.74	$ 1.80
Diluted (in dollars per share)	$ 1.72	$ 1.78
Weighted average common shares outstanding:
Basic (in Shares)	111	112
Diluted (in Shares)	112	113

DGX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 474	$ 686
Accounts receivable, net of allowance for credit losses of $28 and $27 as of March 31, 2024 and December 31, 2023, respectively	1,322	1,210
Inventories	181	190
Prepaid expenses and other current assets	251	286
Total current assets	2,228	2,372
Property, plant and equipment, net	1,810	1,816
Operating lease right-of-use assets	579	602
Goodwill	7,830	7,733
Intangible assets, net	1,192	1,166
Investments in equity method investees	133	135
Other assets	182	198
Total assets	13,954	14,022
Liabilities and Stockholders' Equity
Accounts payable and accrued expenses	1,239	1,359
Current portion of long-term debt	906	303
Current portion of long-term operating lease liabilities	153	153
Total current liabilities	2,298	1,815
Long-term debt	3,804	4,410
Long-term operating lease liabilities	489	503
Other liabilities	817	876
Commitments and contingencies
Redeemable noncontrolling interest	77	76
Quest Diagnostics stockholders’ equity:
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2024 and December 31, 2023; 162 shares issued as of both March 31, 2024 and December 31, 2023	2	2
Additional paid-in capital	2,292	2,320
Retained earnings	8,935	8,825
Accumulated other comprehensive loss	(16)	(14)
Treasury stock, at cost; 51 shares as of both March 31, 2024 and December 31, 2023	(4,781)	(4,826)
Total Quest Diagnostics stockholders' equity	6,432	6,307
Noncontrolling interests	37	35
Total stockholders' equity	6,469	6,342
Total liabilities and stockholders' equity	$ 13,954	$ 14,022

About Quest Diagnostics Inc

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

CEO	Mr. James E. Davis
WEBSITE	questdiagnostics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	40000

Quest Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Quest Diagnostics Inc? What does DGX stand for in stocks?

DGX is the stock ticker symbol of Quest Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quest Diagnostics Inc (DGX)?

As of Tue May 07 2024, market cap of Quest Diagnostics Inc is 15.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers. The fair value of Quest Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quest Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quest Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether DGX is over valued or under valued. Whether Quest Diagnostics Inc is cheap or expensive depends on the assumptions which impact Quest Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DGX.

What is Quest Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, DGX's PE ratio (Price to Earnings) is 17.98 and Price to Sales (PS) ratio is 1.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Quest Diagnostics Inc's stock?

In the past 10 years, Quest Diagnostics Inc has provided 0.11 (multiply by 100 for percentage) rate of return.